Clinical trial
Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML)…
NCT00067028 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00067028 |
|---|---|
| Title | Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML) |
| Official title | A Prospective Randomized Phase I/II Study of Clofarabine (Clo) and Ara-C vs Clo and Ida vs Clo Plus Ida and Ara-C in Patients With First Relapse or First Salvage of Primary Refractory AML; and High-Grade MDS(>/= 10% Blasts); or CML in Myeloid Blasts Phase as Front Line Therapy or in First Salvage. |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Genzyme, a Sanofi Company Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Clofarabine 40mg/m^2, Idarubicin 10mg/m^2, Ara-C 0.75 g/m^2, Clofarabine 22.5mg/m^2, Ara-C 1 g/m^2, Idarubicin 6 mg/m^2 |
| Enrollment | 116 |
| Start date | Dec 1, 2003 |
| Primary completion | Jun 1, 2013 |
| Completion | Jun 1, 2013 |
| First posted | Aug 13, 2003 |
| Last update posted | Dec 8, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: